Immunitas Therapeutics
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | CD161 (KLRB1)Monoclonal antibody | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
17 April 2026PresentationRezorstobartPhase 1/2a IMT-009 (NCT05565417) data at AACR 2026: early anti-tumour activity in heavily pretreated patients
Financial reports
No financial reports recorded.